SAN MARINO, Calif., Feb. 12 /PRNewswire/ -- Epeius Biotechnologies announces the launch of its new informative website, containing an award-winning video and an interactive e-book designed to introduce the general public to the tumor-targeting and cancer-destroying biotechnologies behind the clinical development of Rexin-G. Honored as the first and so far only targeted, genetic medicine that has been validated in clinical trials worldwide (Nature Reviews, Genetics, 2007), Rexin-G is designed to seek-out and destroy metastatic cancers that are resistant to chemotherapy and which have spread throughout the body. The new website is designed to inform the general public of the basic platform biotechnologies that enable the nano-medicine to flow beyond the finest catheter, beyond the reach of the most gifted surgeon, to the very fabric of nature -- and to update prospective patients as to the current availability of Rexin-G in an increasing number of clinical trials conducted in the U.S. and the Republic of the Philippines.
The Rexin-G video is an animated tour-de-force of Science Communications. Winning both the Bronze Telly Award for film and video productions and the Platinum Aurora Award (Best of Show) for excellence in independent film-making, the Rexin-G video is a triumph of Art in the service of Science, in the service of Medicine. As one watches the artful collapsing of a tumor under the onslaught of the targeted genetic medicine, it is interesting to note that the complex mechanisms of cellular apoptosis, focal necrosis, and anti-angiogenesis were beautifully "translated" by a Native American artist/programmer by visualizing and digitizing time-lapse photography that revealed the collapsing of a pumpkin in a field. Likewise, the interactive booklet is a magical work of electronic storytelling, utilizing video stills, laser cut-outs, and other curious means to take the reader/viewer into the center of the cell to view, and to treat, cancer from the inside.
By focusing on informing society and the cancer patient of these newly-emergent, enabling biotechnologies, the accessibility of published scientific literature, and the availability of ongoing clinical trials, Epeius Biotech hopes to establish a new standard of corporate conduct and communications that recognizes the reason and intelligence of each and every cancer patient, the power and grace of an inspired medical mission, and the true value of service in an otherwise graceless age.
Rexin-G is currently in clinical trials in the U.S. It has been granted Orphan Drug Status by the U.S. FDA for three cancer indications: (i) Pancreatic cancer, (ii) Soft Tissue Sarcoma, and (iii) Osteosarcoma. Rexin-G has recently been approved in the Philippines for the treatment of all solid tumors that are refractory to standard chemotherapy. For general information please visit www.epeiusbiotech.com and for detailed information regarding patient eligibility for current clinical trials contact Dr. Erlinda M. Gordon, Medical Director (firstname.lastname@example.org).
*(LOGO 72dpi: Send2Press.com/mediaboom/08-0421-Epeius_72dpi.jpg)
This release was issued on behalf of the above organization by Send2Press(R), a unit of Neotrope(R). http://www.Send2Press.com
|SOURCE Epeius Biotech|
Copyright©2009 PR Newswire.
All rights reserved